Epithelial splicing regulatory proteins 1 (ESRP1) and 2 (ESRP2) suppress cancer cell motility via different mechanisms. - Test2 - elhamkhani - TriplyDB

Epithelial splicing regulatory proteins 1 (ESRP1) and 2 (ESRP2) suppress cancer cell motility via different mechanisms.

Epithelial splicing regulatory proteins 1 (ESRP1) and 2 (ESRP2) suppress cancer cell motility via different mechanisms.

http://www.wikidata.org/entity/Q38964131

about

Actin cytoskeletal control during epithelial to mesenchymal transition: focus on the pancreas and intestinal tract Transcriptomic Profiling of Posterior Polymorphous Corneal Dystrophy.CD44 Splice Variant v8-10 as a Marker of Serous Ovarian Cancer Prognosis.Global profiling of alternative RNA splicing events provides insights into molecular differences between various types of hepatocellular carcinoma Identification of a Novel Human E-Cadherin Splice Variant and Assessment of Its Effects Upon EMT-Related Events.Connecting the dots: chromatin and alternative splicing in EMT.RNA-binding protein CELF1 promotes tumor growth and alters gene expression in oral squamous cell carcinoma.Epigenetic regulation of ZEB1-RAB25/ESRP1 axis plays a critical role in phenylbutyrate treatment-resistant breast cancer.Expression of SRSF3 is Correlated with Carcinogenesis and Progression of Oral Squamous Cell Carcinoma.CD82 suppresses CD44 alternative splicing-dependent melanoma metastasis by mediating U2AF2 ubiquitination and degradation Epithelial splicing regulatory protein 1 and 2 paralogues correlate with splice signatures and favorable outcome in human colorectal cancer.Splicing factor ratio as an index of epithelial-mesenchymal transition and tumor aggressiveness in breast cancer.Epithelial-mesenchymal transition is regulated at post-transcriptional levels by transforming growth factor-β signaling during tumor progression.Isoform switch of CD44 induces different chemotactic and tumorigenic ability in gallbladder cancer.The role of small GTPases of the Rho/Rac family in TGF-β-induced EMT and cell motility in cancer.Connecting myelin-related and synaptic dysfunction in schizophrenia with SNP-rich gene expression hubs.Maid is a negative regulator of transforming growth factor-β-induced cell migration.Splicing-factor alterations in cancers.Aberrant Splicing in Cancer: Mediators of Malignant Progression through an Imperfect Splice Program Shift.EMT and stemness: flexible processes tuned by alternative splicing in development and cancer progression.The Arkadia-ESRP2 axis suppresses tumor progression: analyses in clear-cell renal cell carcinoma IDH1 mutation-associated long non-coding RNA expression profile changes in glioma.The RNA-binding protein ESRP1 promotes human colorectal cancer progression.The ESRP1-GPR137 axis contributes to intestinal pathogenesis.Snail suppresses cellular senescence and promotes fibroblast-led cancer cell invasion.Regulation of epithelial-mesenchymal transition in breast cancer cells by cell contact and adhesion.Dual Roles for Epithelial Splicing Regulatory Proteins 1 (ESRP1) and 2 (ESRP2) in Cancer Progression.Establishment of Synergistic Chemoimmunotherapy for Head and Neck Cancer Using Peritumoral Immature Dendritic Cell Injections and Low-Dose Chemotherapies.Genome-wide screen for differentially methylated long noncoding RNAs identifies Esrp2 and lncRNA Esrp2-as regulated by enhancer DNA methylation with prognostic relevance for human breast cancer.ESRP1 is overexpressed in ovarian cancer and promotes switching from mesenchymal to epithelial phenotype in ovarian cancer cells.Signaling Pathways Driving Aberrant Splicing in Cancer Cells.Mesenchymal splice isoform of CD44 (CD44s) promotes EMT/invasion and imparts stem-like properties to ovarian cancer cells.Silencing the Snail-dependent RNA splice regulator ESRP1 drives malignant transformation of human pulmonary epithelial cells.Organoids with cancer stem cell-like properties secrete exosomes and HSP90 in a 3D nanoenvironment.Alternative-splicing defects in cancer: Splicing regulators and their downstream targets, guiding the way to novel cancer therapeutics.

P2860

Q28082719-5F1398AE-03E8-438F-88F3-41CA46B960E0 Q33847709-6D34DEED-37F2-4EEF-B5FA-ACF1ADAFD84B Q36037993-5B7BFB5B-41E3-4ADC-A1C2-56066E5D9FD5 Q36114523-8A563A84-8AA7-4D90-A44B-65AD074CF179 Q36147466-E76417CC-3C5D-48A4-8B79-F8AB63F13947 Q36441240-545B8EB5-7CC5-42DA-B097-5BCC35DCF667 Q36685461-ECEC4E73-F4CF-49AD-8F34-8FF0BCD64C14 Q36738957-439FE5F3-9B3B-4FA5-B87D-E7E4A72125A8 Q37096920-B1418F44-D5A4-4599-B06D-CC0B8DC34362 Q37276868-FF1347CA-9F2F-4CB2-8754-3A087641D3C1 Q37687476-7C6D2AA1-8501-411F-A952-01980DA27357 Q37709301-C70B8D5D-9653-425D-A6EC-4C201775B4B7 Q38349021-BE063E2C-C003-4F17-B9D0-F81652A75CD4 Q38698070-D31D1EC9-DB45-4947-9A2A-639FCD4EBA13 Q38846822-4C831190-6C8E-4BF6-91FB-AE466A3994E4 Q38850829-A362B420-F1D9-45A9-9102-8E109C1E14DB Q38871732-58C7D3EA-62FE-45AE-A5C0-B2D70E7F682A Q38929098-C1576E9A-09FE-4734-B46B-C66FC93CE033 Q38994370-D3A0D34E-9E22-4182-A1B2-2EE4511A019E Q39109931-BB6AA16F-D414-4F86-90F8-36498CD7D17E Q40368929-4739D751-9E5E-49F6-81FC-8B2EF36C3F13 Q40576605-EB54FB7A-F653-424B-ADF4-A72A2DED902B Q41835902-1D7536EC-2B9C-4B9E-BF18-D853E4DEA1D4 Q41991370-390105F0-63C4-4342-BC54-6A4F781B0CA5 Q42288796-4405F18C-9919-4D88-AE39-2DD5E84FCF7D Q43144068-B874EFBF-2753-49FA-A4FE-1679EA3C923F Q46518039-18301DDA-3EA9-4E76-9F08-68F19DFCC0B6 Q47096374-5C97822D-38B4-4004-97CA-F33B0B41668D Q47111892-CED7202C-CDC9-431D-B1E2-E22F29427909 Q47138140-CF75170F-238B-4D50-ABD7-0D8ACA217DCE Q47246029-11751650-8AAF-4F80-8812-2CAB4C991F87 Q48318565-64E9104F-9FA7-4DB3-B71F-A098E82E9033 Q50066565-DC2DDCD9-92E0-4C5F-9AAB-726A391987B8 Q50133361-EDFE1378-E809-4AE0-9D51-530357DADCA1 Q52564290-A7F31A45-4A96-49E8-8253-0C4A018ED0C4

P2860

Epithelial splicing regulatory proteins 1 (ESRP1) and 2 (ESRP2) suppress cancer cell motility via different mechanisms.

http://www.wikidata.org/entity/Q38964131

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Epithelial splicing regulatory ...... lity via different mechanisms.

@en

type

label

Epithelial splicing regulatory ...... lity via different mechanisms.

@en

prefLabel

Epithelial splicing regulatory ...... lity via different mechanisms.

@en

P1433

Q38964131-DFE1C335-CF49-41DB-A52B-AE38DB4B3CEB

P1476

Q38964131-A46A59AB-7320-4055-BCA4-6F653F3D8722

P2093

Q38964131-0870991C-194C-47A0-BF9F-DAC336110936

Q38964131-0A038ACD-47C9-4623-A9D8-C47707E83906

Q38964131-0E2212FE-7F02-4C3A-AB66-7B8FCF7D679B

Q38964131-263AA0D5-B21A-4567-AEAD-F8F1994115D1

Q38964131-53A8E3E5-C5F6-4B95-8853-FDF01C6F20C5

Q38964131-6B688CED-1FDE-4B6A-973F-8715AA4E9229

Q38964131-87CE9296-7D72-4197-AA51-BBA06B0F387E

Q38964131-881F2E3A-C7C5-4914-8079-C0B5BB61EA6C

P2860

Q38964131-0F772F1D-E68F-480D-A5EB-AF16A78F507D

Q38964131-0FFAF112-9EA5-49B1-9D7A-6AD4EEDA179F

Q38964131-14AF8132-82FF-4B0A-BD02-89933E244FEE

Q38964131-1A6CDF1D-B01D-4055-9EB9-F0737993A576

Q38964131-1B0B1AD3-3CC8-43F6-9F90-44236ECA7EE9

Q38964131-2607708A-8FE8-4FE0-BD73-6E6C4C106252

Q38964131-2FE155F1-7EBE-4838-B111-92911484F8E3

Q38964131-31ADE632-A16C-4D18-A2A4-5949B544B937

Q38964131-410A6994-0E30-4A9D-B539-DC5CBAE97BF2

Q38964131-4326BE73-A066-4C3B-9B42-BEC754EFE919

P304

Q38964131-57291EEE-0013-400E-A8FD-07E0BDE1740F

P31

Q38964131-635D35AB-C911-48C7-978E-389C4155BD50

P356

Q38964131-F32C8841-AE02-4225-8C32-978FAE8549C4

P407

Q38964131-287689EE-83B2-4D9E-8A8E-59936BDAC33F

P433

Q38964131-B303AA8A-7DEE-47A8-8159-CD90D649DD20

P478

Q38964131-B5B501B7-1361-41B4-BB68-49537F062E2D

P50

Q38964131-B54ED1C6-02AD-4C2D-8FD6-1F2905C21CEA

P577

Q38964131-5A07BE27-F5D4-42AE-AC41-429038D77B75

P698

Q38964131-069D635E-A212-442C-AC8E-3BA2F0B25DAE

P932

Q38964131-2DF1DBA7-FD59-49F2-A0A1-1066B3D10E43

P356

JBC.M114.589432

P1433

Journal of Biological Chemistry

P1476

Epithelial splicing regulatory ...... ility via different mechanisms

@en

P2093

Hiroki Ishii

http://www.w3.org/2001/XMLSchema#string

Kei Sakamoto

http://www.w3.org/2001/XMLSchema#string

Keisuke Masuyama

http://www.w3.org/2001/XMLSchema#string

Masao Saitoh

http://www.w3.org/2001/XMLSchema#string

Mitsuyoshi Motizuki

http://www.w3.org/2001/XMLSchema#string

Ryohei Katoh

http://www.w3.org/2001/XMLSchema#string

Shota Tanaka

http://www.w3.org/2001/XMLSchema#string

Tetsuo Kondo

http://www.w3.org/2001/XMLSchema#string

P2860

ESRP1 and ESRP2 are epithelial cell-type-specific regulators of FGFR2 splicing

An Id-like molecule, HHM, is a synexpression group-restricted regulator of TGF-beta signalling

Erk5 controls Slug expression and keratinocyte activation during wound healing

SIP1/ZEB2 induces EMT by repressing genes of different epithelial cell-cell junctions

An EMT-driven alternative splicing program occurs in human breast cancer and modulates cellular phenotype

Alternative splicing of Rac1 generates Rac1b, a self-activating GTPase

Epithelial-mesenchymal transitions in development and disease

Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits

TGF-β regulates isoform switching of FGF receptors and epithelial-mesenchymal transition

The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion

P304

27386-27399

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1074/JBC.M114.589432

http://www.w3.org/2001/XMLSchema#string

P407

P433

40

http://www.w3.org/2001/XMLSchema#string

P478

289

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-08-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25143390

http://www.w3.org/2001/XMLSchema#string

P932

4183779

http://www.w3.org/2001/XMLSchema#string